DOT drug testing is a federally mandated program under 49 CFR Part 40 that applies only to safety-sensitive transportation employees, uses a fixed five-drug panel, a specific chain-of-custody form, and requires review by a Medical Review Officer (MRO). Non-DOT (also called "company" or "employer") drug testing is a voluntary program the employer designs, governed by state law and internal policy rather than Part 40, with no federally required panel, form, or MRO review. The two programs cannot share a specimen, a form, or a result, per 49 CFR 40.13.
For buyers stocking a testing program, this distinction determines which collection cups, forms, and alcohol testing devices you actually need to order, and getting it wrong creates compliance exposure for regulated fleets.
Who Has to Run DOT Testing
DOT testing is required for any employee performing a "safety-sensitive function" in a mode regulated by a DOT operating administration, most commonly commercial motor vehicle (CMV) drivers under FMCSA, along with aviation, rail, transit, pipeline, and maritime workers under their respective agencies. Part 40 itself states its purpose is to tell "all parties who conduct drug and alcohol tests required by Department of Transportation (DOT) agency regulations" how to run those tests (49 CFR 40.1). If a role is not defined as safety-sensitive under a DOT agency rule, DOT testing does not apply to it, and any screening that employer runs is a non-DOT program by default.
The Federal Rulebook Behind DOT Testing
Every procedural detail of a DOT test, who can collect it, what form documents it, which lab can run it, and who reviews the result, is fixed by Part 40. Employers, collectors, and labs have no discretion to substitute their own procedures. That is the core reason DOT programs need dedicated DOT-compliant collection supplies, using anything else risks an invalid test.
What a Non-DOT Program Actually Is
A non-DOT test is any screening an employer runs outside a DOT mandate: pre-employment screening for a warehouse hire, a reasonable-suspicion test at an office, or a broad workplace policy for a distribution company. These programs are shaped by state drug-testing statutes and the employer's own written policy, not Part 40. That gives the employer flexibility, they can choose the drug panel, the collection method, and the consequences for a positive result, but it also means there is no federal floor of procedure protecting the test's defensibility. Many non-DOT employers voluntarily follow DOT-style chain-of-custody practices anyway, because it makes results easier to defend if challenged.
DOT vs Non-DOT at a Glance
| Factor | DOT Testing | Non-DOT Testing |
|---|---|---|
| Who regulates it | 49 CFR Part 40, plus the relevant DOT agency rule (e.g., FMCSA's 49 CFR Part 382) | State law and the employer's written policy |
| Drug panel | Fixed 5-panel: marijuana, cocaine, amphetamines/MDMA, opioids, PCP | Employer's choice, any panel size or substance list |
| Required form | Federal Drug Testing Custody and Control Form (CCF) only | No federally required form; employer or lab's own form |
| Collection rules | Certified collector, strict chain of custody, defined procedures for temperature checks, shy bladder, and observed collections | Set by employer or testing vendor; no federal collection standard |
| Alcohol testing | Breath Alcohol Technician using an evidential breath testing device under Part 40 Subpart M | Employer's chosen method; not governed by Part 40 |
| Result review | Medical Review Officer (licensed physician) reviews every non-negative lab result | No MRO requirement; employer decides how results are reviewed |
| Consequences of a positive | Immediate removal from safety-sensitive duty, SAP evaluation, return-to-duty process | Set entirely by employer policy and applicable state law |
The Panel Difference: Fixed 5-Panel vs Custom
Under 49 CFR 40.85, DOT laboratories must test every specimen for marijuana metabolites, cocaine metabolites, amphetamines (including MDMA/MDA), opioids (including codeine, morphine, 6-acetylmorphine, hydrocodone/hydromorphone, and oxycodone/oxymorphone), and phencyclidine (PCP), each at fixed initial and confirmatory cutoff concentrations. An employer cannot add or drop a drug class from a DOT test. Non-DOT employers, by contrast, can build a panel of any size, a 5-panel, 10-panel, or a custom list built around their industry's risk profile, using drug testing cups configured for whichever substances the policy specifies. For a full breakdown of the specific cutoff levels labs use to call a result positive, see ASC's drug test cutoff levels guide.
Collection Rules: the CCF, Chain of Custody, and the MRO
Every DOT collection must be documented on the Federal Drug Testing Custody and Control Form, not a lab's in-house form and not an expired CCF (49 CFR 40.40). Collectors follow a defined procedure for temperature strips, split specimens, and problem collections like shy bladder, covered in detail in ASC's DOT urine collection procedure guide. Once the lab reports a result, a Medical Review Officer, a licensed physician trained in substance abuse disorders and controlled substance pharmacology, reviews every non-negative result and any invalid or adulterated specimen finding before it reaches the employer (49 CFR 40.3; MRO duties detailed at 49 CFR 40.123). Non-DOT programs have no CCF requirement and no mandated MRO review; some employers use an MRO anyway for consistency and legal defensibility, but it is a policy choice, not a federal rule.
Alcohol Testing: DOT Program vs Company Policy
DOT alcohol testing is conducted under Part 40 Subpart M using an evidential breath testing (EBT) device administered by a trained Breath Alcohol Technician. A screening result of 0.02 or higher triggers a confirmation test. Under FMCSA's rule implementing Part 40 for commercial drivers, a confirmed result of 0.02 to 0.039 requires the employer to pull the driver from safety-sensitive duty for at least 24 hours, and a confirmed result of 0.04 or higher requires immediate removal from duty and is treated as a violation requiring the DOT return-to-duty process (49 CFR 382.505). Non-DOT alcohol testing has no federally set thresholds or device requirements; the employer's policy defines the cutoff and the consequence. Employers building either program can source devices through ASC's breathalyzers collection.
Oral Fluid: What Changed in 2023, and What Hasn't Yet
DOT published a final rule in May 2023 amending Part 40 to permit oral fluid as an alternate specimen type for DOT drug testing, alongside urine (88 FR 27596). That rule is in effect, but oral fluid collection is not yet operational for DOT testing: the rule requires HHS to certify at least two laboratories, a primary lab and a split-specimen lab, before any DOT-regulated employer can use it, and as of this writing HHS has not certified the required labs. Employers should keep running urine collections until DOT confirms certified labs are in place; ASC will update sourcing guidance the moment oral fluid becomes usable for DOT programs.
What a Positive Result Means for Each Program
A confirmed positive DOT test, or an alcohol result of 0.04 or higher, means immediate removal from safety-sensitive duty, evaluation by a Substance Abuse Professional (SAP), and a defined return-to-duty process before the employee can perform safety-sensitive work again. These consequences are set by the DOT agency regulation for that mode, not by employer discretion. A positive non-DOT result triggers whatever consequence the employer's written policy specifies, termination, a last-chance agreement, referral to an assistance program, and that consequence must still comply with applicable state drug-testing laws.
Choosing the Right Program for Your Workforce
If any employee in the role performs a safety-sensitive function under a DOT agency rule, that testing must run on the DOT program; there is no opt-out or hybrid version. Employers building or refreshing a DOT compliance program should start from ASC's DOT pre-employment drug screen solution, which is built around the CCF-documented, five-panel process regulators expect. For the broader workforce outside DOT-covered roles, a non-DOT panel gives HR and safety managers the flexibility to screen for what actually matters to their risk profile, while still following defensible collection practices.
Frequently Asked Questions
What is the main difference between DOT and non-DOT drug testing?
DOT drug testing is required by federal regulation (49 CFR Part 40) for safety-sensitive transportation employees and follows a fixed panel, a mandatory federal form, and mandatory MRO review. Non-DOT testing is a voluntary employer program governed by state law and company policy, with no federally set panel, form, or review requirement.
Does a DOT drug test require a specific form?
Yes. Every DOT collection must be documented on the Federal Drug Testing Custody and Control Form (CCF). Employers cannot use a non-federal form or an expired CCF for a DOT test, and the CCF cannot be used for non-DOT testing.
Can a non-DOT test result change or override a DOT test result?
No. Federal rules state that no one is permitted to change or disregard the results of a DOT test based on a non-DOT test result, and the two specimens and test processes must be kept completely separate.
What drugs does the DOT 5-panel test screen for?
Under 49 CFR 40.85, DOT laboratories test for marijuana metabolites, cocaine metabolites, amphetamines (including MDMA/MDA), opioids (including codeine, morphine, 6-acetylmorphine, hydrocodone/hydromorphone, and oxycodone/oxymorphone), and phencyclidine (PCP).
Is oral fluid testing allowed for DOT drug tests yet?
DOT authorized oral fluid as a specimen type in a May 2023 final rule, but it cannot be used for DOT testing until HHS certifies the required laboratories. As of this writing, that certification has not happened, so DOT programs must continue using urine collection.
What alcohol concentration fails a DOT alcohol test?
These thresholds come from the DOT agency rule for each transportation mode, not from Part 40 itself. Under FMCSA's rule for commercial drivers (49 CFR 382.505), a confirmed result of 0.02 to 0.039 requires removal from safety-sensitive duty for at least 24 hours, and a confirmed result of 0.04 or higher requires immediate removal from duty and is treated as a violation requiring the DOT return-to-duty process.
Compliance and Accuracy Note
This article summarizes selected provisions of 49 CFR Part 40 and related DOT agency rules for general informational purposes and is not legal advice. Regulations and HHS laboratory certifications change; employers should confirm current requirements against the official Code of Federal Regulations and their DOT agency before building or updating a testing program. Drug and alcohol test products screen for the presence of substances and do not diagnose impairment, addiction, or a specific individual's drug use; all non-negative screening results require confirmation and, for DOT programs, Medical Review Officer review before any employment action is taken.
